Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us

COVID-19 updates

Picture

COVID-19 Update #136 6/30/2022

6/29/2022

 
COVID-19 Vaccines
 
An FDA review of data available for the Omicron variant vaccines from Moderna and Pfizer-BioNtech found that both vaccines improved the neutralizing antibody response to Omicron BA.1. The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted 19-2, on 6/28/2022, to recommend incorporating a component of the omicron variant into future COVID booster vaccines. The Omicron BA.4 and BA.5 subvariants now comprise more than 50% of COVID-19 cases. If the FDA requests a new booster vaccine to include these variants, Moderna and Pfizer-BioNTech would be able to create the vaccines by October. VRBPAC recommended a new booster be bivalent and contain BA.4 or BA.5 subvariants of Omicron.
  • The FDA found that an investigational 50 mcg bivalent vaccine from Moderna, used as a fourth dose, elicited 75% higher antibodies for the Omicron BA.1 subvariant. 
  • An investigational 30 mcg Omicron specific vaccine from Pfizer-BioNTech elicited 56% more antibodies. Pfizer-BioNTech presented data that demonstrated activity against the BA.4 and BA.5 subvariants in mice.
  • An investigational COVID-19 vaccine from Novavax, that uses a protein-based vaccine, demonstrated antibodies that remained active against Omicron and its subvariants. Novavax will not have data on an Omicron specific vaccine until September.
  • Moderna announced additional interim data from an 800 patient, Phase II/III trial, where an investigational bivalent COVID-19 vaccine, containing a combination of the original vaccine and an Omicron variant specific vaccine, used as a booster dose, increased neutralizing antibodies against BA.4 and BA.5 by 5.4-fold in all participants regardless of prior infection.
  • Pfizer and BioNTech announced that in a 1,234 patient, Phase II/III trial, an investigational Omicron specific vaccine, given as a fourth booster dose, increased neutralizing antibody titers by 13.5 with a 30 mcg dose and 19.6 fold with a 60 mcg dose against Omicron BA.1. A vaccine that combined the Omicron vaccine with the original vaccine increased neutralizing antibody titers by 9.1 and 10.9-fold increase against Omicron with 30 mcg and 60 mcg doses.​
Sanofi and GSK announced that in the 13,000 patient, Phase III, VAT08 trial (NCT04904549), primary vaccination with two doses of their bivalent COVID-19 vaccine resulted in vaccine efficacy of 64.7% against any symptomatic COVID-19 disease, 72% effectiveness in preventing Omicron variant symptomatic cases.
 
A case–control test-negative study by the CDC found vaccine effectiveness to prevent COVID-19 hospitalization in infants born to mothers immunized with an mRNA vaccines to be 80% during the Delta variant dominant period and 38% during the Omicron dominant period. Administration, of the second COVID-19 vaccine dose after 20 weeks of pregnancy was more effective than when given before the first 20 weeks (69% vs. 38%).
 
An in-vitro analysis of neutralizing antibody titers in serum from 27 patients that had received two doses of the Pfizer-BioNTech COVID-19 vaccine and 27 patients who had been infected with the BA.1 or BA.2 subvariant found that titers were lower for BA.2.12.1, BA.4, and BA.5 subvariants than BA.1 and BA.2.


Comments are closed.
    Stay informed, subscribe to the Prescribe Right Pharmaceutical Pipeline Tracker

    Archives

    January 2023
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.